Given that GLS2 appears to play a larger role than GLS1 in glutamine consumption in HCC cell lines, we investigated whether GLS2 inhibition could have greater clinical efficacy in blunting HCC development. The gene discussed is GLS2; the disease is hepatocellular carcinoma.